Branch² Intelligence
Dr. Reddy's Shares Extend Fall For Second Day As Semaglutide Quality Concerns Prevail
Key takeaway
Dr. Reddy's shares fall 2% on semaglutide quality concerns, risking supply disruption.
- Step 1Quality concerns at Dr. Reddy's semaglutide plant trigger FDA scrutiny and potential supply disruption.
- Step 2US GLP-1 supply tightens, benefiting competitors with approved product (Sun Pharma, Novo Nordisk).
- Step 3Indian API suppliers to Dr. Reddy's face order cancellations; contract manufacturers lose revenue.
Source: IN:NDTV Profit
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.